Drugs.com - Clinical Trials Clinical trial news from Drugs.com. Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
-
Janssen Presents Longer-Term Data for Tecvayli Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma
on June 6, 2023 at 1:06 am
CHICAGO, June 5, 2023. The Janssen Pharmaceutical Companies of Johnson & Johnson announced today long-term data from the pivotal Phase 1/2 MajesTEC-1 study showing the sustained efficacy and safety of TECVAYL0I (teclistamab-cqyv) in the...
-
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
on June 5, 2023 at 3:06 am
REDWOOD CITY, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) announced the final overall survival (OS) results of the JUPITER-02 study presented today at the American Society for Clinical...
-
Datopotamab Deruxtecan Combinations Showed Encouraging Tumour Responses in Patients with Advanced Non-Small Cell Lung Cancer in TROPION-Lung02 Phase Ib Trial
on June 5, 2023 at 1:06 am
5 June 2023 -- Updated results from the TROPION-Lung02 Phase Ib trial showed that, with additional enrolment and follow-up from the initial presentation, datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without...
-
Biogen Provides Update on Parkinson’s Disease Clinical Development Program
on June 5, 2023 at 1:06 am
June 5, 2023 -- As part of its ongoing Research & Development (R&D) prioritization initiative and resource allocation, Biogen announced plans to revise the clinical development program for BIIB122, a small molecule inhibitor of leucine-rich...
-
Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma
on June 4, 2023 at 9:06 pm
BOSTON, June 4, 2023. Servier, a leader in oncology committed to bringing innovative therapies to the patients we serve, today presented results from the pivotal Phase 3 INDIGO clinical trial investigating vorasidenib, an investigational, oral,...
-
New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached after 33.6 Months of Follow-Up with First-Line Use of RYBREVANT® (amivantamab-vmjw) and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR-Mutated Advanced Non-Small Cell Lung Cancer
on June 4, 2023 at 1:06 am
CHICAGO, June 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term results from the CHRYSALIS study, which showed the combination of RYBREVANT® (amivantamab-vmjw) and lazertinib*, a...
-
Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma
on June 3, 2023 at 1:06 am
CHICAGO, June 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of TECVAYLI® (teclistamab-cqyv), a first-in-class BCMAxCD3 bispecific...
-
Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma
on June 3, 2023 at 1:06 am
CHICAGO, June 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the pivotal Phase 1/2 MonumenTAL-1 study of the investigational bispecific antibody talquetamab in the treatment of...
-
Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
on June 3, 2023 at 12:06 am
JERSEY CITY, N.J., June 2, 2023. MEDSIR announced today the positive results of the PHERGain trial. This study is the first to use an adaptive design that tailors treatment in the neoadjuvant/adjuvant setting of patients with HER2-positive early...
-
Study Finds Surgical Treatment of Sleep Apnea More Effective than CPAP Therapy in Preventing the Onset of Type 2 Diabetes
on June 1, 2023 at 10:06 pm
CAMBRIDGE, Mass., June 1, 2023. TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, enabled researchers at Hospital Quirónsalud Marbella and Hospital Campo de...
-
NIH’s ComboMATCH Initiative Will Test New Drug Combinations Guided by Tumor Biology
on June 1, 2023 at 12:06 am
June 1, 2023 -- The National Cancer Institute (NCI) has launched a large precision medicine cancer initiative to test the effectiveness of treating adults and children with new drug combinations that target specific tumor alterations....
-
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Aztreonam-Avibactam (ATM-AVI) Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
on June 1, 2023 at 12:06 am
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone NEW YORK--(BUSINESS WIRE) June 01, 2023 --...
-
Update on Brazikumab Development Programme
on June 1, 2023 at 12:06 am
1 June 2023 -- AstraZeneca today announced the discontinuation of the brazikumab inflammatory bowel disease (IBD) development programme, an anti-IL-23 monoclonal antibody, being investigated for the treatment of Crohn’s disease (CD) and...
-
NIH Scientists Find Treatment for Rare Genetic Skin Disorder
on May 31, 2023 at 11:05 pm
May 31, 2023 -- Researchers at the National Institutes of Health and their colleagues have identified genomic variants that cause a rare and severe inflammatory skin disorder, known as disabling pansclerotic morphea, and have found a potential...
-
Research and Pipeline Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
on May 30, 2023 at 11:05 pm
Study demonstrates statistically significant and clinically relevant reduction in annualized bleeding rate compared to prophylaxis and on-demand intravenous regimens Marstacimab, if approved, has the potential to become the first once-weekly...
-
First Subject Dosed in a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Vaccine Developed for the Prevention of Shingles
on May 30, 2023 at 9:05 pm
MORRISVILLE, N.C., May 30, 2023. Immorna, a rapidly expanding biotechnology company focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the first subject has been dosed in the Company's...
-
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
on May 29, 2023 at 9:05 pm
MELBOURNE, Australia, May 29, 2023. Amplia Therapeutics Limited ("Amplia" or the "Company") is pleased to announce new data showing the efficacy of its investigational FAK inhibitor, AMP945, in a preclinical model of pancreatic cancer, when used in...
-
CHOP Researchers Show that IgA Fine Tunes the Body's Interactions with Microbes
on May 26, 2023 at 9:05 pm
PHILADELPHIA, May 26, 2023. IgA deficiency is the most common primary immune deficiency worldwide, but its presentation has puzzled physcians and researchers. Some with the disorder present with symptoms like recurrent infections, autoimmune...
-
Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
on May 25, 2023 at 9:05 pm
TARRYTOWN, N.Y., May 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data from two Phase 2 expansion dose cohorts evaluating investigational linvoseltamab (formerly REGN5458) in patients with...
-
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
on May 25, 2023 at 8:05 pm
TARRYTOWN, N.Y., May 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive data from three independent cohorts evaluating an investigational combination of LAG-3 inhibitor fianlimab and PD-1 inhibitor...
